WDLangbein

/Bill Langbein

About Bill Langbein

Before starting SanaCurrents, William (Bill) Langbein spent more than 20 years as a life science business journalist, with stops at California Medicine, In Vivo and Reuters Health. During that time, he wrote on genomic discoveries, the transition of the pharmaceutical companies to rely more on biologics, and the dawn of precision medicine, through which most drug developers came to recognize a one-drug-for-all approach would no longer work. One constant truth he learned is smaller companies deliver the most innovation and highest value to patients and investors. Yet because of the inherent volatility of biopharma and medical devices, small companies typically fly under the radar of investors. The emergence of precision medicine, however, reduces the volatility of small cap companies and increases the potential for strong returns. SanaCurrents was founded to identify the undervalued therapies that would benefit patients and investors the most.

Hemophilia Treatment Company Catalyst Biosciences’ Antibody Update May Catalyze Shares

Catalyst Biosciences, Inc. (NASDAQ:CBIO) , a company that is developing improved [...]

Karyopharm’s Cancer Drug Achieves Impressive Results

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reported impressive results on December 1, 2018 [...]

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – 3Q 2019 catalyst, CBD treatment for Fragile X

3Q ‘19 catalyst, CBD treatment for Fragile X SanaCurrents is [...]

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – December Catalyst, Lymphoma Phase IIb Trial

December catalyst, lymphoma phase IIb trial SanaCurrents assigns a pivotal [...]

SanaCurrents BioTech Research Service Inaugural Reports on EIDX and GLMD

Last week, Galmed Pharmaceuticals  (NASDAQ:GLMD) shares climbed as high as [...]

Update on Eidos Therapeutics after Positive Phase II Results

Eidos Therapeutics, Inc. (NASDAQ:EIDX) shares are up as much as [...]

Galmed (GLMD) – November Catalyst: Aramchol

November Catalyst: Aramchol SanaCurrents forecasts an advantageous probability Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) [...]

Eidos Therapeutics (EIDX) – 4Q Catalyst: AG10 phase II data

4Q Catalyst: AG10 phase II data Based on its analytics [...]

Top